



## Corrigendum

## Corrigendum to ‘Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults $\geq 50$ years of age: A randomized trial’ [Vaccine 36 (2018) 4278–4286]

Céline Maréchal <sup>a,\*</sup>, Himal Lal <sup>b,1</sup>, Airi Poder <sup>c</sup>, Murdo Ferguson <sup>d</sup>, Igwebuike Enweonye <sup>e</sup>, Thomas C. Heineman <sup>b,2</sup>, Caroline Hervé <sup>f</sup>, Paul Rheault <sup>g</sup>, Jaak Talli <sup>h</sup>, Dominique Wauters <sup>f</sup>, Lidia Oostvogels <sup>f,3</sup>

<sup>a</sup> Business and Decision Life Sciences for GSK, Wavre, Belgium

<sup>b</sup> GSK, King of Prussia, PA, USA

<sup>c</sup> Clinical Research Center, Tartu, Estonia

<sup>d</sup> Colchester Research Group, Truro, Nova Scotia, Canada

<sup>e</sup> GSK, Amsterdam, the Netherlands

<sup>f</sup> GSK, Wavre, Belgium

<sup>g</sup> Medisor Research Inc., Sudbury, Ontario, Canada

<sup>h</sup> Innomedica Medical Center, Tallinn, Estonia



The authors regret an error in the footnote of [Table 2](#): the adjusted GMC values were not only adjusted for baseline value, but also for age.

The authors would like to apologize for any inconvenience caused.

### Appendix A. Supplementary material

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.vaccine.2019.01.022>.

DOI of original article: <https://doi.org/10.1016/j.vaccine.2018.05.110>

\* Corresponding author. Current address: GSK, Avenue Fleming 20, Wavre 1300, Belgium.

E-mail address: [celine.x.marechal@gsk.com](mailto:celine.x.marechal@gsk.com) (C. Maréchal).

<sup>1</sup> Current address: Pfizer Inc., 500 Arcola Rd, Collegeville, PA 19426, USA.

<sup>2</sup> Current address: Halozyme Therapeutics, 11388 Sorrento Valley Road, San Diego, CA 02121, USA.

<sup>3</sup> Current address: CureVac AG, Paul-Ehrlich-Straße 15, Tübingen 72076, Germany.

<https://doi.org/10.1016/j.vaccine.2019.01.022>

0264-410X/© 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

**Table 2**

VRRs, anti-gE ELISA antibody GMCs (1 month after second RZV vaccination) and serotype-specific MOPA GMTs (1 month after PPSV23 vaccination) (according-to-protocol cohort for immunogenicity).

<i>RZV response</i>						
	Co-Ad		Control		GMC <sub>Control</sub> /GMC <sub>Co-Ad</sub> <sup>*</sup> (95% CI)	
	N	Value	N	Value	Value	
<b>VRR, % (95% CI)</b>	401	98.3 ( <b>96.4</b> <sup>†</sup> –99.3)	402	98.3 (96.4–99.3)	–	
<b>Adjusted<sup>†</sup> GMC, mIU/mL (95% CI)</b>	401	49569.0 (46641.4–52680.4)	402	50474.5 (47497.4–53638.2)	1.02 (0.93– <b>1.11</b> <sup>††</sup> )	
<i>PPSV23 response</i>						
	Serotype	Co-Ad		Control		GMT <sub>Control</sub> /GMT <sub>Co-Ad</sub> <sup>**</sup> (95% CI)
		N	Value	N	Value	Value
<b>Adjusted<sup>**</sup> MOPA GMT (95% CI)</b>	<b>1</b>	408	65.6 (55.2–77.9)	411	67.6 (56.9–80.2)	1.03 (0.81– <b>1.31</b> <sup>†††</sup> )
	<b>3</b>	408	108.9 (95.7–124.1)	411	105.0 (92.2–119.5)	0.96 (0.80– <b>1.16</b> <sup>††</sup> )
	<b>4</b>	408	1117.2 (963.1–1296.1)	409	1264.1 (1089.9–1466.2)	1.13 (0.92– <b>1.40</b> <sup>†††</sup> )
	<b>5</b>	408	159.8 (135.1–188.9)	411	152.6 (129.1–180.3)	0.96 (0.75– <b>1.21</b> <sup>††</sup> )
	<b>6B</b>	408	1666.6 (1418.0–1958.6)	409	1536.8 (1307.9–1805.7)	0.92 (0.73– <b>1.16</b> <sup>††</sup> )
	<b>7F</b>	407	2324.7 (2033.3–2657.9)	409	2491.3 (2179.8–2847.5)	1.07 (0.89– <b>1.29</b> <sup>†††</sup> )
	<b>9V</b>	406	1970.3 (1700.9–2282.3)	410	1911.8 (1651.6–2212.9)	0.97 (0.79– <b>1.19</b> <sup>††</sup> )
	<b>14</b>	407	2678.1 (2339.4–3065.8)	411	2610.1 (2281.6–2986.0)	0.97 (0.81– <b>1.18</b> <sup>††</sup> )
	<b>18C</b>	405	1099.8 (952.8–1269.6)	411	1040.9 (902.7–1200.4)	0.95 (0.77– <b>1.16</b> <sup>††</sup> )
	<b>19A</b>	406	1350.5 (1180.0–1545.7)	406	1558.6 (1361.8–1783.8)	1.15 (0.95– <b>1.40</b> <sup>†††</sup> )
	<b>19F</b>	407	914.1 (793.4–1053.3)	409	938.2 (814.6–1080.7)	1.03 (0.84– <b>1.25</b> <sup>††</sup> )
	<b>23F</b>	405	419.1 (354.9–494.9)	410	372.8 (316.0–439.8)	0.89 (0.70– <b>1.12</b> <sup>††</sup> )

Co-Ad, study group in which participants received the first dose of RZV and PPSV23, co-administered at Day 0 and the second dose of RZV at Month 2; Control, study group in which participants received PPSV23 at Day 0, the first dose of RZV at Month 2 and second dose of RZV at Month 4. VRR, vaccine response rate; gE, glycoprotein E; ELISA, enzyme-linked immunosorbent assay; GMC, geometric mean concentration; MOPA, multiplexed opsonophagocytic assay; GMT, geometric mean titers; N, number of participants with both pre- and post-vaccination results available; CI, confidence interval; \*, adjusted for baseline value and age; \*\*, adjusted for baseline value.

†, co-primary objective considered met if  $\geq 60\%$ ; ††, co-primary objective considered met if  $< 1.5$ ; †††, co-primary objective considered met if  $< 2$ .

VRR, the percentage of participants who had at least: (i) a 4-fold increase in the post-RZV dose 2 anti-gE antibody concentration as compared to the pre-vaccination anti-gE antibody concentration, for participants who were seropositive at baseline, or (ii) a 4-fold increase in the post-RZV dose 2 anti-gE antibody concentrations as compared to the anti-gE antibodies' cut-off value for seropositivity, for participants who were seronegative at baseline.